BRPI0907220A2 - métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf - Google Patents

métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf

Info

Publication number
BRPI0907220A2
BRPI0907220A2 BRPI0907220-9A BRPI0907220A BRPI0907220A2 BR PI0907220 A2 BRPI0907220 A2 BR PI0907220A2 BR PI0907220 A BRPI0907220 A BR PI0907220A BR PI0907220 A2 BRPI0907220 A2 BR PI0907220A2
Authority
BR
Brazil
Prior art keywords
bone loss
methods
treating bone
csf antagonist
loss disorders
Prior art date
Application number
BRPI0907220-9A
Other languages
English (en)
Inventor
R. Bebbington Christopher
T. Yarranton Geoffrey
Original Assignee
Kalobios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40673999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907220(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalobios Pharmaceuticals, Inc. filed Critical Kalobios Pharmaceuticals, Inc.
Publication of BRPI0907220A2 publication Critical patent/BRPI0907220A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf". a presente invenção refere-se a antagonistas de gm-csf que podem ser usados para o tratamento de distúrbios de perda óssea, tais co-mo osteopenia. consequentemente, a invenção fornece métodos de admi-nistrar um antagonista de gm-csf, por exemplo, um anticorpo de gm-csf, a um paciente que tem um distúrbio de perda óssea e composições farma-cêuticas compreendendo tais antagonistas.
BRPI0907220-9A 2008-01-15 2009-01-15 métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf BRPI0907220A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2121808P 2008-01-15 2008-01-15
US61/021,218 2008-01-15
PCT/US2009/031126 WO2009091905A1 (en) 2008-01-15 2009-01-15 Methods of treating bone-loss disorders using a gm-csf antagonist

Publications (1)

Publication Number Publication Date
BRPI0907220A2 true BRPI0907220A2 (pt) 2019-02-26

Family

ID=40673999

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907220-9A BRPI0907220A2 (pt) 2008-01-15 2009-01-15 métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf

Country Status (10)

Country Link
US (2) US20090181020A1 (pt)
EP (1) EP2245062B1 (pt)
JP (1) JP2011510015A (pt)
CN (1) CN101932603A (pt)
AT (1) ATE555131T1 (pt)
AU (1) AU2009206082A1 (pt)
BR (1) BRPI0907220A2 (pt)
CA (1) CA2711763A1 (pt)
EA (1) EA201001162A1 (pt)
WO (1) WO2009091905A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
DK2976359T4 (da) * 2013-03-20 2022-06-13 Genzyme Corp Fremgangsmåder til behandling af osteogenesis imperfecta
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CN107655871A (zh) * 2017-09-12 2018-02-02 重庆医科大学 一种阿仑膦酸钠的高灵敏宽检测范围荧光检测新方法
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
CN117126277B (zh) * 2023-10-26 2024-01-23 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011404A1 (en) * 1992-11-19 1994-05-26 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
AU2003217386B2 (en) * 2002-02-13 2008-06-26 Ludwig Institute For Cancer Research Humanized GM-CSF antibodies
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
ES2432173T3 (es) * 2006-11-21 2013-12-02 Kalobios Pharmaceuticals, Inc. Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF

Also Published As

Publication number Publication date
WO2009091905A1 (en) 2009-07-23
JP2011510015A (ja) 2011-03-31
EP2245062A1 (en) 2010-11-03
US20090181020A1 (en) 2009-07-16
CN101932603A (zh) 2010-12-29
EP2245062B1 (en) 2012-04-25
CA2711763A1 (en) 2009-07-23
US20120009191A1 (en) 2012-01-12
AU2009206082A1 (en) 2009-07-23
EA201001162A1 (ru) 2010-12-30
ATE555131T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
EA201071231A1 (ru) Карбоксамидные соединения для лечения метаболических растройств

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]